Clinical trials: Patients With Locally Advanced Rectal Cancer
Gastrointestinal Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05262491
- Testing
- BL-B01D1
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Rectal Cancer Patients, Rectal Cancer Stage II
Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression
This study is a prospective, multicenter, open-label, randomized controlled Phase II clinical trial enrolling patients with locally advanced rectal cancer who tested positive for YWHAB (tyrosine 3-monooxygenase/tryptophan…
- Conditions
- Rectal Cancer Patients, Rectal Cancer Stage II, Rectal Cancer Stage III
- Trial name
- NCT07176182
- Testing
- mFOLFOX regimen combined with Citrus Flavone Tablets (Alvenor) neoadjuvant treatment group, mFOLFOX regimen neoadjuvant therapy group
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Anal Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003652
- Testing
- cisplatin, fluorouracil, neoadjuvant therapy
- Where
- 48 sites in France
- Volunteers
- 350 people
- Sponsor
- UNICANCER
Breast Cancer, Colorectal Cancer
Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer
This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc.
- Conditions
- Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- CDX1307-02 (NCT00648102)
- Testing
- CDX-1307
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Celldex Therapeutics
Colorectal Cancer
SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic or locally recurrent colorectal cancer. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Trial name
- NCT00006001
- Testing
- semaxanib
- Where
- 10 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer Patients
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
Research Objective:To investigate the efficacy and safety of the "total neoadjuvant chemoradiotherapy combined with immunotherapy" regimen for the treatment of locally advanced rectal cancer with high-risk features for…
- Trial name
- TNT-Immunity (NCT07214142)
- Testing
- PD-1
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
Rectal Cancer
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
This is a phase II, prospective, open label, one-center study for evaluation of the addition of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced rectal cancer patients.
- Trial name
- NCT03921684
- Testing
- Capecitabine, Radiation therapy, mFOLFOX6
- Where
- Israel
- Volunteers
- 29 people
- Sponsor
- Baruch Brenner
Colorectal Cancer, Gastric Cancer
Low-dose Immunotherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMMR Cancers
It is planned to study the effectiveness of low-dose immunotherapy (IT) nivolumab 40 mg for either 2 courses of therapy or 6 courses as preoperative therapy in patients with dMMR/MSI locally advanced CRC.
- Trial name
- NIVO402025 (NCT07542262)
- Testing
- Low-dose nivolumab, Low-dose nivolumab with/without chemotherapy, Low-dose nivolumab combined with chemotherapy
- Where
- Russia
- Volunteers
- 128 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Unresectable Colorectal Cancer, Colorectal Cancer (Locally Advanced or Metastatic)
FMT Combined With Standard First-Line Therapy in Initially Unresectable Colorectal Cancer
This clinical trial evaluates the efficacy and safety of adding fecal microbiota transplantation (FMT) to first-line standard of care for patients with initially unresectable colorectal cancer (CRC).
- Trial name
- NCT07509398
- Testing
- Standard First-Line Therapy, FMT Combined with Standard First-Line Therapy
- Volunteers
- 220 people
- Sponsor
- Shanghai 10th People's Hospital
Rectal Cancer
Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management
The study is designed to test the hypothesis that patients with Locally advanced rectal cancer ( LARC) treated with Total neoadjuvant therapy (TNT) and Total mesorectal excision (TME) or Non-operative management (NOM) will have…
- Trial name
- NCT02008656
- Testing
- Oxaliplatin (OXAL), 5-Fluorouracil (5-FU), Leucovorin
- Where
- 26 sites in United States
- Volunteers
- 358 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Patients With Locally Advanced Rectal Cancer
GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.
The evaluation of the tumor response to chemoradiotherapy/total neoadjuvant therapy (CRT/TNT) remains a challenge. The integration of a blood-based biomarker such as ctDNA with clinico-radiological tools could offer the potential…
- Trial name
- REVEAL (NCT05674422)
- Testing
- total neoadjuvant therapy
- Where
- 15 sites in Spain
- Volunteers
- 120 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Locally Advanced Rectal Cancer (LARC)
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients
This is a phase II, multicenter, randomized (2:1) controlled, clinical trial to evaluate the preliminary efficacy and safety of consolidation chemotherapy (XELOX) plus dostarlimab after standard long-course CRT (ARM A) compared…
- Trial name
- IMMUNOSTAR (NCT07381777)
- Testing
- XELOX (Capecitabine and Oxaliplatin), Dostarlimab
- Where
- 30 sites in Italy
- Volunteers
- 270 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Colon Cancer, Rectal Cancer
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
The purpose of the Phase Ib portion is to find out the highest dose of study drug that can safely be given when tested in a small group of subjects.
- Trial name
- NCT01347645
- Testing
- FOLFIRI, E7820
- Where
- 38 sites in United States, Argentina and 4 more
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Rectal Cancer
Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Rectal Cancer
This is a nonrandomised pilot trial to establish the role of intravenous cetuximab when added to a schedule of capecitabine plus pelvic radiation in patients who have locally advanced primary resectable rectal cancers.
- Trial name
- XERT (NCT00689702)
- Testing
- cetuximab, capecitabine
- Where
- Slovenia
- Volunteers
- 43 people
- Sponsor
- Institute of Oncology Ljubljana
Rectal Carcinoma
Neoadjuvant Treatment for Advanced Rectal Carcinoma
The purpose of the study is to compare pre-operative radio-chemotherapy (RT + capecitabine) to a short course RT associated with a delayed surgery, with two primary objectives: the efficacy evaluation (rate of R0 resection) and…
- Trial name
- NACRE (NCT02551237)
- Testing
- 50 Gy, Capecitabine, 25 Gy
- Where
- 37 sites in France
- Volunteers
- 103 people
- Sponsor
- UNICANCER
Colorectal Cancer
FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as FR901228, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00077337
- Testing
- romidepsin
- Where
- 88 sites in United States
- Sponsor
- SWOG Cancer Research Network
Metastatic Colorectal Cancer
A Study of ES104 in Patients With Metastatic Colorectal Cancer
The purpose of this open-label, Multicenter Phase I/II study is to evaluate the safety, tolerability, preliminary anti-tumor efficay, pharmacokinetics, anti-drug antibodies and biomarkers of ES104 in patients with unresectable…
- Trial name
- NCT05167448
- Testing
- ES104
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.
Metastatic Colorectal Cancer
Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer
Investigators propose to assess, retrospectively (from 1/7/2009) and prospectively (up to 31/12/2013,) the safety and tolerability profile (number of participants with adverse events) of standard chemotherapy and anti-angiogenic…
- Trial name
- NCT01811108
- Where
- 6 sites in Greece
- Volunteers
- 670 people
- Sponsor
- Hellenic Oncology Research Group
Colorectal Cancer
A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advanced or Metastatic Colorectal Cancer.
To assess the safety and preliminary efficacy of TQB2930 and chemotherapy with or without bevacizumab in sparticipants with HER2-Abnormally Expressed locally advanced or metastatic colorectal cancer (CRC).
- Trial name
- NCT07653685
- Testing
- TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection, TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)
- Where
- 31 sites in China
- Volunteers
- 71 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Colorectal Cancer
ISIS 2503 in Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer
RATIONALE: ISIS 2503 may kill cancer cells by inhibiting a gene that promotes the development and growth of cancer. PURPOSE: Phase II trial to study the effectiveness of ISIS 2503 in treating patients who have metastatic and/or…
- Trial name
- NCT00004193
- Testing
- ISIS 2503
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham